Bausch Health Companies Inc BHC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
Five TSX Stocks Finished Well Ahead of the Composite in a Week of Results and a Rate Hike
Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
Bausch Health Announces US$50 Million Share Repurchase Program
BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
Trading Information
- Previous Close Price
- $8.42
- Day Range
- $8.21–8.48
- 52-Week Range
- $4.33–9.04
- Bid/Ask
- $8.42 / $8.48
- Shares Outstanding
- 374.27M
- Market Cap
- $3.17B
- Volume/Avg
- 3M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 1.73
- Price/Sales
- 0.29
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 20,300
- Website
- https://www.bauschhealth.com
Valuation
Metric | BHC |
|---|---|
Price/Earnings (Normalized) | 1.73 |
Price/Book Value | — |
Price/Sales | 0.29 |
Price/Cash Flow | 1.27 |
Price/Earnings
BHC
Financial Strength
Metric | BHC |
|---|---|
Quick Ratio | 1.06 |
Current Ratio | 1.56 |
Interest Coverage | 0.75 |
Quick Ratio
BHC
Profitability
Metric | BHC |
|---|---|
Return on Assets (Normalized) | 7.25% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 14.62% |
Return on Assets
BHC
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|<&!xh^c | LOCK|$tVZ | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|bl%%x<@ | LOCK|>N>v^ | $49B | |||
| Haleon PLC ADR HLN | LOCK|%N>B?q | LOCK|t@^ | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|&$^^R<@ | LOCK|W?$ | $34B | |||
| Viatris Inc VTRS | LOCK|@>g!$&< | LOCK|PM$ | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|>G& | LOCK|$@ | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|qR$n$# | LOCK|K< | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|&%BT!R< | LOCK|Z!& | $4B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|$h#QT#X | LOCK|@j&Yw | $2B | |||
| Perrigo Co PLC PRGO | LOCK|>c$Y@Qp | LOCK|Q> | $2B |